ライフサイエンスコーパス: antithymocyte

1 Patients receiving antithymocyte antibody had a lower recurrence rate than

2 ing responses to horse and rabbit polyclonal antithymocyte antibody preparations.

3 Antithymocyte/antilymphocyte globulins are polyclonal an

4 ic CMVIG and induction with high-dose rabbit antithymocyte globulin (>10 mg/kg) were associated with

5 e randomly assigned to receive either rabbit antithymocyte globulin (1.5 mg per kilogram of body weig

6 e the murine monoclonal anti-CD3 antibody or antithymocyte globulin (15.2% versus 21.1%; P=0.061).

7 ence was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P=0.63).

8 emental thymic irradiation (7 Gy on day -1), antithymocyte globulin (50 mg/kg on days -2, -1, and 0),

9 nditioning regimen used was CYC (200 mg/kg), antithymocyte globulin (90 mg/kg), and methylprednisolon

10 gimen included cyclophosphamide (200 mg/kg), antithymocyte globulin (90 mg/kg), and, for 1 patient, t

11 ng, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin (90 mg/kg).

12 with cyclophosphamide (200 mg/kg) and equine antithymocyte globulin (90 mg/kg).

13 orin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux,

14 one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilogram of

15 groups based on induction immunosuppression: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29

16 Antithymocyte globulin (ATG) + cyclosporine is effective

17 However, our randomized trial comparing antithymocyte globulin (ATG) and Cy was terminated early

18 otal body irradiation, cyclophosphamide, and antithymocyte globulin (ATG) and was followed by transpl

19 Eighty-two patients received rabbit antithymocyte globulin (ATG) as part of the conditioning

20 ate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clo

21 Lymphocyte depletion with antithymocyte globulin (ATG) can be complicated by syste

22 C using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) followed by the infusion of

23 ), HLA mismatch (RR = 8.9, P < .001), use of antithymocyte globulin (ATG) for graft versus host disea

24 ndomized clinical trial comparing ABX-CBL to antithymocyte globulin (ATG) for treatment of steroid-re

25 We previously showed that antithymocyte globulin (ATG) given with total body irrad

26 Antithymocyte globulin (ATG) has been used in allogeneic

27 Antithymocyte globulin (ATG) has recently been populariz

28 Daclizumab and antithymocyte globulin (ATG) have been shown to reduce a

29 The impact of antithymocyte globulin (ATG) in the setting of a myeloab

30 ences were not seen among patients receiving antithymocyte globulin (ATG) induction (aRR for AR, 1.16

31 rawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin.

32 Total lymphoid irradiation (TLI) with antithymocyte globulin (ATG) is a unique regimen that pr

33 Antithymocyte globulin (ATG) is used as induction therap

34 Polyclonal antithymocyte globulin (ATG) is widely used as an anti-T

35 udies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for redu

36 We evaluated the effect of antithymocyte globulin (ATG) on anti-human leukocyte ant

37 We studied the impact of early, late, and no antithymocyte globulin (ATG) on immune reconstitution an

38 Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can b

39 iated with a clinically relevant response to antithymocyte globulin (ATG) or cyclosporine immunosuppr

40 tion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell a

41 Immunosuppressive therapy with antithymocyte globulin (ATG) plus cyclosporine is an eff

42 Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte

43 The addition of antithymocyte globulin (ATG) to a regimen of high-dose c

44 ddition of low, nondepleting doses of rabbit antithymocyte globulin (ATG) to human peripheral blood m

45 ) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-m

46 ith an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (

47 ed with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) were given kidney transplan

48 data support replacing BuCy2 with or without antithymocyte globulin (ATG) with Bu-Flu with or without

49 e fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine

50 ant total lymphoid irradiation (TLI), rabbit antithymocyte globulin (ATG), and a single donor blood t

51 ed the ability of the immune-depleting agent antithymocyte globulin (ATG), as well as the mobilizatio

52 erapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield toleranc

53 oning regimen--whole body irradiation (WBI), antithymocyte globulin (ATG), extracorporeal immunoadsor

54 ive nonmyeloablative protocols using TLI and antithymocyte globulin (ATG), followed by allogeneic hem

55 se using various combinations of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimula

56 -lymphoid irradiation (TLI), with or without antithymocyte globulin (ATG), have been shown to develop

57 Thymoglobulin, a rabbit polyclonal antithymocyte globulin (ATG), is a widely used induction

58 s, induction with antilymphocyte globulin or antithymocyte globulin (ATG), or use of ATG or OKT3 for

59 nts receiving total body irradiation without antithymocyte globulin (ATG), whereas the relapse risk w

60 tosus, conditioned with a regimen containing antithymocyte globulin (ATG), who developed factor VIII

61 al greater than 80 days using a steroid-free antithymocyte globulin (ATG)-based induction regimen (AT

62 res of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell r

63 he cardiovascular consequences of polyclonal antithymocyte globulin (ATG)-induced immune modification

64 some of whom were undergoing treatment with antithymocyte globulin (ATG).

65 of groups 2 and 3 received CY combined with antithymocyte globulin (ATG).

66 Patients received immunosuppression with antithymocyte globulin (ATG)/cyclosporine (CsA) or cyclo

67 experience using dual-induction therapy with antithymocyte globulin (ATG)/daclizumab (Dac) (each with

68 ody irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclopho

69 clophosphamide (200 mg/kg) and either equine antithymocyte globulin (ATG, 90 mg/kg) or rabbit ATG (6

70 de (200 mg/kg), methylprednisolone (4 g) and antithymocyte globulin (ATG; 90 mg/kg) or myeloablative

71 s according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n

72 splantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-

73 003 to 2004 received no induction (n=4,364), antithymocyte globulin (ATG; n=4,930), interleukin-2 rec

74 t and 19 lung transplant recipients received antithymocyte globulin (ATGAM or thymoglobulin) as induc

75 ipients additionally received horse anti-pig antithymocyte globulin (days -2, -1, and 0).

76 Fludarabine, busulfan, and antithymocyte globulin (Fd/Bu/ATG) was associated with t

77 m immunosuppressive therapy (IST) with horse antithymocyte globulin (h-ATG) and cyclosporine (CsA) ca

78 arly phase of allogeneic HCT were receipt of antithymocyte globulin (HR, 22.77 [95% CI, 4.85-101.34])

79 nce interval [CI]=1.16-1.81), induction with antithymocyte globulin (HR: 1.43, 95% CI=1.075-1.94), an

80 Mouse antithymocyte globulin (mATG) prevents, as well as rever

81 usulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antithymocyte globulin (n = 1).

82 py was with MMF, tacrolimus, prednisone, and antithymocyte globulin (n=109) or OKT3 (n=2).

83 eukin (IL)-2-receptor antagonists (n=217) or antithymocyte globulin (n=64).

84 (P = 0.046) as well as those having received antithymocyte globulin (P < 0.001) were more likely to d

85 LA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant p

86 atologic improvement after administration of antithymocyte globulin (P = 0.0015).

87 mber 2008 who received induction with rabbit-antithymocyte globulin (r-ATG), alemtuzumab, or an inter

88 ategories: no-induction, alemtuzumab, rabbit antithymocyte globulin (r-ATG), and interleukin-2 recept

89 randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab

90 we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and basilixim

91 ts were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) or nonde

92 emtuzumab induction was compared with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Genzyme] o

93 ategies have not been established for rabbit antithymocyte globulin (rATG) after heart transplantatio

94 Rabbit antithymocyte globulin (rATG) and horse ATG (hATG) are w

95 reatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous immunoglob

96 Alemtuzumab and rabbit antithymocyte globulin (rATG) are commonly used for indu

97 Despite the prevalent use of rabbit antithymocyte globulin (rATG) as an induction agent in k

98 safety and efficacy of induction with rabbit antithymocyte globulin (RATG) compared with interleukin-

99 ients who received either steroids or rabbit antithymocyte globulin (RATG) for orthotopic liver trans

100 recipients who received rituximab and rabbit antithymocyte globulin (rATG) in combination as inductio

101 free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthotopic li

102 Optimal dosing of rabbit antithymocyte globulin (rATG) induction therapy in kidne

103 ge, we developed a protocol to extend rabbit antithymocyte globulin (rATG) induction therapy into the

104 5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly due to i

105 Induction rabbit antithymocyte globulin (rATG) is largely used in renal a

106 who were randomized to receive either rabbit antithymocyte globulin (RATG) or steroids as induction t

107 ere evaluated before and after adding rabbit antithymocyte globulin (rATG) to mixed lymphocyte co-cul

108 single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance arm (pa

109 Thymoglobulin, rabbit antithymocyte globulin (RATG), has been shown to be effe

110 man leukocyte antigen (HLA) mismatch, rabbit antithymocyte globulin (RATG), interleukin-2 receptor an

111 proliferation by Ki-67(+) T cells in rabbit antithymocyte globulin (rATG)-treated patients the first

112 bined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG).

113 exposed (4.23%) versus not exposed to rabbit antithymocyte globulin (rATG; 0.53%; P=0.019) or SPK (9.

114 iximab (1998), daclizumab (1998), and rabbit antithymocyte globulin (rATG; 1999) replaced antilymphoc

115 ed to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living d

116 Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in

117 tion of donor marrow (RR = 12.7), and use of antithymocyte globulin (RR = 6.4) or anti-CD3 monoclonal

118 imary kidney transplant recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) v

119 eatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hours befo

120 Recipients were treated with 7 doses of antithymocyte globulin (Thymoglobulin, day 1 to 9), siro

121 omized, international study comparing rabbit antithymocyte globulin (TMG) and basiliximab (BAS) induc

122 mphoid irradiation of 80 cGy for 10 days and antithymocyte globulin 1.5 mg/kg/d for 5 days.

123 otal body irradiation, cyclophosphamide, and antithymocyte globulin [ATG] with cyclosporine A and met

124 Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppress

125 (ATS) (the murine preclinical equivalent of antithymocyte globulin [ATG]) facilitates immune toleran

126 ual care (the control group was treated with antithymocyte globulin [ATG]).

127 omes after in vivo T-cell depletion (n = 584 antithymocyte globulin [ATG]; n = 213 alemtuzumab) were

128 A dose of 40 mg/kg per day of antithymocyte globulin administered for 4 days, 10 to 12

129 f haploidentical marrow grafts, who received antithymocyte globulin after bone marrow transplantation

130 ng regimen of total lymphoid irradiation and antithymocyte globulin allowed engraftment of the donor'

131 teroid withdrawal protocol; 9 of 11 received antithymocyte globulin and 2 received basiliximab induct

132 included induction with a steroid taper and antithymocyte globulin and anti-CD20 monoclonal antibody

133 national study, we compared short courses of antithymocyte globulin and basiliximab in patients at hi

134 ransplantation, immunosuppression (generally antithymocyte globulin and ciclosporin), and high-dose c

135 st-line immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporin and is manifested

136 immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expa

137 nts with severe aplastic anemia treated with antithymocyte globulin and cyclosporine have durable rec

138 Antithymocyte globulin and cyclosporine restore hematopo

139 standard immunosuppressive regimens, such as antithymocyte globulin and cyclosporine.

140 All patients were treated with antithymocyte globulin and cyclosporine.

141 ined a well-established adult mouse model of antithymocyte globulin and DBM treatment and show that e

142 let Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet c

143 re less than 150 and 250, respectively, with antithymocyte globulin and intravenous immunoglobulin in

144 We conclude that induction with antithymocyte globulin and maintenance immunosuppression

145 received additional immune suppression with antithymocyte globulin and methylprednisolone in the ear

146 sisted of high-dose cyclophosphamide, equine antithymocyte globulin and pretransplant thymic irradiat

147 The use of antithymocyte globulin and prolonged exposure to gancicl

148 , contributes to the therapeutic efficacy of antithymocyte globulin and suggest that time-dependent w

149 rapy agents, growth factor combinations, and antithymocyte globulin appear promising and are reviewed

150 ition of melphalan, and the incorporation of antithymocyte globulin appear to have contributed to bet

151 eroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for

152 CMV disease, attributable to high levels of antithymocyte globulin at the time of T cell infusion.

153 reatment study, 34% of patients treated with antithymocyte globulin became transfusion independent.

154 ymic irradiation before transplantation, and antithymocyte globulin before and after transplantation.

155 cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.

156 ome received busulfan, cyclophosphamide, and antithymocyte globulin before receiving cord-blood trans

157 t recipients who received induction doses of antithymocyte globulin combined with maintenance immunot

158 alemtuzumab-based conditioning with standard antithymocyte globulin conditioning regimens, lower rate

159 A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute

160 Treatment with antithymocyte globulin did not seem to be detrimental be

161 Ganciclovir-resistant patients received more antithymocyte globulin during induction (70+/-44 vs. 45+

162 h about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours.

163 Rabbit antithymocyte globulin facilitates apoptosis of alloreac

164 herefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus monotherapy

165 tations from unrelated donors and were given antithymocyte globulin for GVHD prophylaxis.

166 The total amount of antithymocyte globulin given to each CD3 monitored patie

167 drugs such as tacrolimus, mycophenolate, or antithymocyte globulin go on shortage.

168 The antithymocyte globulin group and the basiliximab group h

169 The antithymocyte globulin group, as compared with the basil

170 r between the two groups, patients receiving antithymocyte globulin had a greater incidence of infect

171 g high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy.

172 ely) were low and associated with the use of antithymocyte globulin in 91% of patients.

173 ired steroid therapy and one required rabbit antithymocyte globulin in addition to MMF and steroids.

174 with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients.

175 onmyeloablative conditioning, and absence of antithymocyte globulin in the conditioning regimen.

176 results demonstrate that in a murine system, antithymocyte globulin induces cells with suppressive ac

177 ere enrolled in a prospective study in which antithymocyte globulin induction and 6 days of corticost

178 uired in SPK transplant recipients receiving antithymocyte globulin induction and maintenance immuno-

179 Immunosuppression consisted of antithymocyte globulin induction and maintenance with si

180 ntenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus and siro

181 Almost all patients received antithymocyte globulin induction and were maintained on

182 Immunosuppression consisted of antithymocyte globulin induction followed by mycophenola

183 ined PAK (n=47) transplants receiving rabbit antithymocyte globulin induction from June 1998 to June

184 CI], 1.2 to 6.6; P=0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio,

185 nor, thin ureters at kidney transplantation, antithymocyte globulin induction therapy, blood transfus

186 An early steroid withdrawal regimen with antithymocyte globulin induction was associated with exc

187 od II (post-August 2001) with alemtuzumab or antithymocyte globulin induction with steroid avoidance.

188 k renal transplant patients usually involves antithymocyte globulin induction with triple drug mainte

189 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, and mycoph

190 pression consisted of quadruple therapy with antithymocyte globulin induction, tacrolimus, MMF, and p

191 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, mycophenol

192 yclosporine and corticosteroids after rabbit antithymocyte globulin induction.

193 All patients received antithymocyte globulin induction.

194 tient received methylprednisolone and rabbit antithymocyte globulin intravenously during scalp prepar

195 Antithymocyte globulin is frequently used as a component

196 Induction therapy with rabbit antithymocyte globulin may achieve a short-term decrease

197 CMVIG and appropriate induction with rabbit antithymocyte globulin may be important to reduce CMV in

198 nt pretreatment with a single dose of rabbit antithymocyte globulin or alemtuzumab and posttransplant

199 Describe the safety and efficacy of antithymocyte globulin or alemtuzumab preconditioning, s

200 e fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab.

201 n the recipient are depleted by a polyclonal antithymocyte globulin or an anti-T cell immunotoxin.

202 fetil were required as well as either rabbit antithymocyte globulin or interleukin-2 receptor antibod

203 fractory cases, alternative regimens such as antithymocyte globulin or monoclonal antibody therapy ha

204 received methylprednisolone, and 11 received antithymocyte globulin or OKT3.

205 unosuppressive regimens that included rabbit antithymocyte globulin or tacrolimus/mycophenolate combi

206 hosphamide, and 6.5 mg/kg intravenous rabbit antithymocyte globulin or to receive 1.0 g/m(2) intraven

207 should be considered for a second course of antithymocyte globulin plus cyclosporin, although respon

208 enrolled in immunosuppression protocols with antithymocyte globulin plus cyclosporine for correlation

209 onsisting of busulfan, cyclophosphamide, and antithymocyte globulin plus or minus etoposide.

210 lant, and patients did not routinely receive antithymocyte globulin posttransplant.

211 efine the efficacy of a busulfan/fludarabine/antithymocyte globulin RIC regimen in pediatric patients

212 Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15

213 ipheral CD3 lymphocytes to rationally adjust antithymocyte globulin therapy in this patient populatio

214 CD3 monitoring of antithymocyte globulin therapy in thoracic organ recipie

215 rotocol applied including plasmapheresis and antithymocyte globulin treatment as well as cyclophospha

216 th or without endarteritis responded to OKT3/antithymocyte globulin treatment equally well (61% versu

217 Although in vitro antithymocyte globulin treatment resulted in a dramatic

218 the patients) was defined as requirement for antithymocyte globulin treatment within 2 weeks after co

219 Age, history of antithymocyte globulin use, smoking, and history of canc

220 with Aspergillus colonization, use of rabbit antithymocyte globulin was associated with 4-fold risk o

221 -2-receptor induction with daclizumab versus antithymocyte globulin was independently associated with

222 ortional hazard model, treatment with rabbit antithymocyte globulin was significantly associated with

223 Historically, antithymocyte globulin was used when patients did not re

224 With CD3 monitoring, the doses of antithymocyte globulin were reduced from 10-15 mg/kg to

225 er ex vivo nor in vivo T-cell depletion (eg, antithymocyte globulin) convincingly improved outcomes.

226 vidualized conditioning and serotherapy (eg, antithymocyte globulin), nutritional status, exercise, h

227 nduction therapy (antilymphocyte globulin or antithymocyte globulin), whereas LRD recipients did not.

228 nal induction therapy (basiliximab or rabbit antithymocyte globulin).

229 and consecutive LT patients receiving rabbit antithymocyte globulin+/-rituximab induction were studie

230 With the use of rabbit antithymocyte globulin+/-rituximab induction, overall lo

231 Antithymocyte globulin, 40 mg/kg of body weight, given d

232 ession, all patients received induction with antithymocyte globulin, a brief taper of intravenous sol

233 tion, the ATG group (13 recipients) received antithymocyte globulin, although the LOCD2b group (10 re

234 n posttransplant total lymphoid irradiation, antithymocyte globulin, and a single infusion of ACI per

235 I and thymic irradiation, pretransplantation antithymocyte globulin, and immunoadsorption of anti-Gal

236 total body irradiation, thymic irradiation, antithymocyte globulin, and peritransplant CD154 blockad

237 nt after conditioning with cyclophosphamide, antithymocyte globulin, and thymic irradiation.

238 tion therapy consisting of a 5-day course of antithymocyte globulin, as compared with basiliximab, re

239 splant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, mycopheno

240 (700 cGy) irradiation, T cell depletion with antithymocyte globulin, complement depletion with cobra

241 total body irradiation, thymic irradiation, antithymocyte globulin, donor bone marrow transplantatio

242 The regimen consisted of antithymocyte globulin, fludarabine, cyclophosphamide, a

243 otal lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-m

244 re acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma ce

245 ven patients received at least one course of antithymocyte globulin, Minnesota antilymphocyte globuli

246 1997 using a similar induction protocol with antithymocyte globulin, mycophenolate mofetil, prednison

247 le body and thymic irradiation, splenectomy, antithymocyte globulin, pharmacologic immunosuppression

248 out granulocyte colony-stimulating factor or antithymocyte globulin, respectively.

249 Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate mofeti

250 itioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cel

251 h anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-

252 To examine whether antithymocyte globulin-induced regulatory cells might be

253 ession was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases.

254 as carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzumab mon

255 were mostly cyclophosphamide with or without antithymocyte globulin.

256 grade 2A rejection successfully treated with antithymocyte globulin.

257 ther 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin.

258 men included busulfan, cyclophosphamide, and antithymocyte globulin.

259 nsity conditioning with cyclophosphamide and antithymocyte globulin.

260 ablative dosages of busulfan, melphalan, and antithymocyte globulin.

261 0 mg/kg cyclophosphamide and 90 mg/kg equine antithymocyte globulin.

262 mg/kg cyclophosphamide, and 90 mg/kg equine antithymocyte globulin.

263 isting of cyclophosphamide, fludarabine, and antithymocyte globulin.

264 1 g methylprednisolone, and 90 mg/kg equine antithymocyte globulin.

265 myelodysplasia, or renal allografts received antithymocyte globulin.

266 renal allograft recipients who had received antithymocyte globulin.

267 ntation with busulfan, cyclophosphamide, and antithymocyte globulin.

268 duced-intensity conditioning, and the use of antithymocyte globulin.

269 leukocyte antigen mismatch, age, and use of antithymocyte globulin.

270 mib, methylprednisone, rituximab, and rabbit antithymocyte globulin.

271 id irradiation, cyclophosphamide, and rabbit-antithymocyte globulin.

272 d elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, previously

273 erapy with Minnesota antilymphocyte globulin/antithymocyte globulin/OKT3 in most cases and maintenanc

274 Polyclonal antithymocyte globulins (ATGs) are used clinically to pr

275 Antithymocyte globulins (ATGs) are used to prevent and t

276 Rabbit-generated antithymocyte globulins (ATGs), which target human T cel

277 Polyclonal antithymocyte globulins (AThG) are a subset of antilymph

278 -) and 104 seropositive recipients receiving antithymocyte globulins (R+/ATG).

279 Immunosuppression included antithymocyte globulins and bone-marrow infusion then st

280 Immunosuppression with antithymocyte globulins and cyclosporine is effective at

281 89 kidney transplant recipients treated with antithymocyte globulins and prednisone.

282 With antithymocyte globulins and steroids, clinically suspect

283 Polyclonal antithymocyte globulins have been assumed to deplete or

284 Thus, in both murine and human systems, antithymocyte globulins not only deplete T cells, but al

285 time, delayed graft function, induction with antithymocyte globulins, acute rejection before month 3

286 Selected patients respond to antithymocyte globulins, and thrombopoietin receptor ago

287 uccessful induction therapy using two rabbit antithymocyte globulins.

288 ate mofetil, prednisone, and, for induction, antithymocyte globulins.

289 imus, mycophenolate mofetil, prednisone, and antithymocyte globulins.

290 ant total lymphoid irradiation (TLI), rabbit antithymocyte or antilymphocyte globulin (RATG or RALG),

291 A rabbit antithymocyte polyclonal antibody or basiliximab, an int

292 intraoperative administration of polyclonal antithymocyte preparations may reduce the incidence of D

293 total lymphoid irradiation (TLI) and rabbit antithymocyte serum (ATS) (the murine preclinical equiva

294 Peritransplant treatment with antithymocyte serum (ATS) and posttransplantation admini

295 tion of donor spleen or donor bone marrow in antithymocyte serum (ATS) treated recipients.

296 ne release induced by OKT3 was compared with antithymocyte serum (ATS) using an in vitro whole blood

297 one marrow to augment skin graft survival in antithymocyte serum (ATS)-treated recipients is dependen

298 ng regimen of total lymphoid irradiation and antithymocyte serum (TLI/ATS) in mice that has been rece

299 tation of donor Treg proliferation after TLI/antithymocyte serum is IL-4 dependent.

300 tioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-ve